Traditionally, treatment for chronic conditions addressed symptoms or was disease modifying and required lifelong periodic administration and recurring costs. This research extends a previous study by analyzing member retention for adult patients with certain rare diseases.
Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts
This JMCP study compares pay-for-success and pay-for-failure models to identify the short- and long-term incentives for each that manufacturers and payers should consider when developing value-based contracts. More research is needed on the effect of different types of value-based contract schemes on cost and clinical outcomes.
Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts
This JMCP study compares pay-for-success and pay-for-failure models to identify the short- and long-term incentives for each that manufacturer and payer should when developing value-based contracts. More research is needed on the effect of different types of value-based contract schemes on cost and clinical outcome.
Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.
Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.
Major reasons for the slow uptake of outcomes-based risk-sharing agreements in the U.S. are regulatory issues, operational requirements, and deficits in information sharing, according to a literature review published in JMCP.
Major reasons for the slow uptake of outcomes-based risk-sharing agreements in the U.S. are regulatory issues, operational requirements, and deficits in information sharing, according to a literature review published in JMCP.
AMCP webinar that reviewed proceedings from this Partnership Forum.
AMCP webinar that reviewed proceedings from this Partnership Forum.
Partnership Forum: Implementing value-based reimbursement models for both pharmaceuticals and medical care poses significant challenges and opportunities, and depends on integrated delivery networks (IDNs) to execute the processes and programs. Industry thought leaders convened to discuss the issues.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide information on the application of value-based contracts (VBCs) for insulin pricing initiatives. The shift in payment models is expanding beyond the delivery of health care services to encompass models of compensation between payers and biopharmaceutical manufacturers.
Proceedings: AMCP Partnership Forum: Advancing Value-Based Contracting